Summit Healthcare Acquisition Corp (YS) Stock Analysis
Verdict: AVOID
A critical liquidity crunch and $414M debt load overshadow high gross margins, making insolvency a higher probability than a turnaround.
Investment score: 22/100
Analysis as of
Is Summit Healthcare Acquisition Corp stock worth reviewing? The TradeMates thesis
YS Biopharma is facing an existential financial crisis. While revenue slightly increased to $614M, cash reserves collapsed by 88% in 12 months to just $28M. With over $414M in total debt and $138M in annual cash burn, the model sees a near-certain need for massive dilution or restructuring.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Summit Healthcare Acquisition Corp opportunities and risks
What speaks for YS
- High-Value PIKA Platform Intellectual Property
What speaks against YS
- Imminent Cash Runway Exhaustion
Peers and competitors
- 775.HK
- 1061.HK
- 3681.HK
- 690.HK
- 8158.HK
Frequently asked questions about Summit Healthcare Acquisition Corp (YS)
Is YS stock a good investment?
The TradeMates model rates Summit Healthcare Acquisition Corp as AVOID with an investment score of 22/100. YS Biopharma is facing an existential financial crisis. While revenue slightly increased to $614M, cash reserves collapsed by 88% in 12 months to just $28M. With over $414M in total debt and $138M in annual cash burn, the model sees a near-certain need for massive dilution or restructuring. This is algorithmic model output, not personal investment advice.
Is YS stock a buy?
The TradeMates model verdict for YS is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.